Detalhe da pesquisa
1.
Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer ß-lactam or ß-lactam/ß-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.
J Antimicrob Chemother
; 79(1): 82-95, 2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962080
2.
Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers.
Anaerobe
; 77: 102617, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35940371
3.
Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.
Infect Dis Ther
; 12(1): 95-107, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35854204
4.
Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer.
Infect Dis Ther
; 12(1): 209-225, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36443547
5.
Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile-A Retrospective Observational Study.
Open Forum Infect Dis
; 9(12): ofac622, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519119
6.
Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Infect Dis Ther
; 11(1): 111-126, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292496
7.
Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes.
Open Forum Infect Dis
; 9(10): ofac435, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36267250
8.
Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life.
J Patient Rep Outcomes
; 6(1): 49, 2022 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567724
9.
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
J Am Heart Assoc
; 10(20): e020474, 2021 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34612065
10.
Risk assessment of post-discharge mortality among recently hospitalized Medicare heart failure patients with reduced or preserved ejection fraction.
Curr Med Res Opin
; 36(2): 179-188, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31469001
11.
Correction to: Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.
Infect Dis Ther
; 12(1): 109-110, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459384
12.
Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
Am J Manag Care
; 24(6): e175-e182, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29939507
13.
Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Infect Dis Ther
; 11(1): 127, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034290
14.
Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure.
Curr Med Res Opin
; 33(11): 2027-2038, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28704074
15.
Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts.
Adv Ther
; 34(1): 261-276, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27933568
16.
Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life.
J Manag Care Spec Pharm
; 22(12): 1446-1456, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27882835